HANGZHOU TIGERMED CO. H 1 (5HZ1) - Total Assets
Based on the latest financial reports, HANGZHOU TIGERMED CO. H 1 (5HZ1) holds total assets worth €28.80 Billion EUR (≈ $33.67 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HANGZHOU TIGERMED CO. H 1 - Total Assets Trend (2021–2025)
This chart illustrates how HANGZHOU TIGERMED CO. H 1's total assets have evolved over time, based on quarterly financial data. Also see HANGZHOU TIGERMED CO. H 1 market cap and net worth for the company's overall valuation and market capitalisation.
HANGZHOU TIGERMED CO. H 1 - Asset Composition Analysis
Current Asset Composition (December 2025)
HANGZHOU TIGERMED CO. H 1's total assets of €28.80 Billion consist of 21.8% current assets and 78.2% non-current assets. Review HANGZHOU TIGERMED CO. H 1 balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 6.3% |
| Accounts Receivable | €1.41 Billion | 5.0% |
| Inventory | €41.50 Million | 0.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €276.31 Million | 1.0% |
| Goodwill | €3.52 Billion | 12.4% |
Asset Composition Trend (2021–2025)
This chart illustrates how HANGZHOU TIGERMED CO. H 1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See HANGZHOU TIGERMED CO. H 1 (5HZ1) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HANGZHOU TIGERMED CO. H 1's current assets represent 21.8% of total assets in 2025, a decrease from 45.7% in 2021.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2025, down from 36.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 8.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 12.4% of total assets.
HANGZHOU TIGERMED CO. H 1 Competitors by Total Assets
Key competitors of HANGZHOU TIGERMED CO. H 1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A
|
Germany | €17.91 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €88.84 Million |
|
Gencurix Inc
KQ:229000
|
Korea | ₩31.17 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
HANGZHOU TIGERMED CO. H 1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.30 | 1.62 | 1.43 |
| Quick Ratio | 2.28 | 1.61 | 1.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.75 Billion | €2.26 Billion | €2.31 Billion |
HANGZHOU TIGERMED CO. H 1 - Advanced Valuation Insights
This section examines the relationship between HANGZHOU TIGERMED CO. H 1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | €28.36 Billion |
| Market Capitalization | $713.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values HANGZHOU TIGERMED CO. H 1's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: HANGZHOU TIGERMED CO. H 1's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for HANGZHOU TIGERMED CO. H 1 (2021–2025)
The table below shows the annual total assets of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €28.36 Billion ≈ $33.15 Billion |
-1.09% |
| 2024-12-31 | €28.67 Billion ≈ $33.52 Billion |
-3.40% |
| 2023-12-31 | €29.68 Billion ≈ $34.70 Billion |
+8.14% |
| 2022-12-31 | €27.45 Billion ≈ $32.09 Billion |
+15.61% |
| 2021-12-31 | €23.74 Billion ≈ $27.76 Billion |
-- |
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more